SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Evotec branches services into India

By Kirsty Barnes , 18-Jul-2007

Germany-based Evotec has branched out its contract services into India, forming a joint venture with local firm Research Support International (RSI) in a bid to cut costs.

Together the two contract research organisations (CROs) will now offer the design, synthesis and management of compound libraries from newly constructed laboratories in Mumbai, with the aim of providing international clients with a "low cost structure" option for these services.

 

 

 

The venture, called Evotec-RSIL, will design compound libraries of low hundreds to thousands of compounds per scaffold by accessing chemistries already validated at Evotec and/or RSIL, as well as offering library management services, in which it will be able to analyse and purify large screening libraries in a cost efficient manner, said Evotec.

 

 

 

"The pharmaceutical industry is seeking cost efficient solutions for the continual enhancement of their screening libraries," the firm said.

 

 

 

RSI has been operating in the region offering such services for 20 years and Evotec has already collaborated with large pharma firms in this field such as Bayer, Merck & Co. and Roche.

 

 

 

In related news, Evotec has also recently announced that the expansion of its good manufacturing practice (GMP) sterile manufacturing facility in Glasgow, Scotland is now complete and the site is fully operational with double the capacity.

 

 

 

The facility serves Evotec's formulations business, which provides services for the development of formulations of parenteral drugs and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials. A particular specialty is the development and sterile manufacture of lyophilised (freeze-dried) formulations.

 

 

 

"The expansion of the facilities is in response to the demand from clients for clinical supplies of liquid and lyophilised drug product," said the firm.

 

 

 

"These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities."

 

Related products